Maria Rivas Buys 1,000 Shares of Cooper Companies (NASDAQ:COO) Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Maria Rivas bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $82.13 per share, for a total transaction of $82,130.00. Following the acquisition, the director directly owned 11,141 shares of the company’s stock, valued at approximately $915,010.33. The trade was a 9.86% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Cooper Companies Stock Performance

Cooper Companies stock opened at $82.75 on Friday. The stock has a 50-day simple moving average of $74.70 and a 200 day simple moving average of $72.03. The stock has a market capitalization of $16.22 billion, a price-to-earnings ratio of 44.02, a P/E/G ratio of 2.36 and a beta of 1.05. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $100.24.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the firm earned $1.04 EPS. The company’s revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies announced that its board has approved a stock buyback plan on Wednesday, September 17th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Wellington Management Group LLP boosted its holdings in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after buying an additional 4,756,178 shares during the last quarter. Sustainable Growth Advisers LP acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $240,881,000. JANA Partners Management LP bought a new position in Cooper Companies during the 3rd quarter worth approximately $166,917,000. Capital World Investors boosted its stake in Cooper Companies by 25.7% during the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after acquiring an additional 2,159,233 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Cooper Companies by 98.8% during the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after purchasing an additional 1,683,561 shares during the period. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on COO shares. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price objective (up previously from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 price target (up previously from $94.00) on shares of Cooper Companies in a research note on Friday, December 5th. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Mizuho set a $100.00 price objective on Cooper Companies and gave the stock an “outperform” rating in a research report on Friday, December 5th. Finally, KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $90.15.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.